Crucell's Quinvaxem looks secure after settlement
This article was originally published in Scrip
Executive Summary
Crucellhas resolved litigation surrounding the sole production site worldwide for its paediatric vaccine Quinvaxem, removing a potential threat to the manufacture of the pentavalent product.